Value ad(imab)

Adimab VCs will be in the black by next year thanks to tech transfer deals

Adimab LLC's VCs expect to be in the black starting next year thanks to the antibody company's three recent tech transfer deals, including one last week with Novo Nordisk A/S. Adimab hopes the deals will mark the start of a steady flow of dividend checks to its investors.

CEO Tillman Gerngross said Adimab's business development strategy from the start has been

Read the full 609 word article

How to gain access

Continue reading with a
two-week free trial.